Loading
A phase 1 trial of CYNK-001 run by Celularity Incorporated, terminated.
Natural Killer Cell (CYNK-001) Infusions in Adults with AML is a phase 1 interventional study registered as NCT04310592 by Celularity Incorporated, with 27 participants enrolled, started 2020-03-12. Conditions recorded: Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML and Refractory AML. Interventions recorded: CYNK-001.
Shares CYNK-001, Celularity, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CYNK-001, Celularity and the tag pipeline.
Shares CYNK-001, Celularity and the tag pipeline.
Shares Leukaemia (all types), Acute myeloid leukaemia and the tag pipeline.
Shares Leukaemia (all types), Acute myeloid leukaemia and the tag pipeline.
Shares Leukaemia (all types), Acute myeloid leukaemia and the tag pipeline.
Shares Leukaemia (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Leukaemia (all types), Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/